Cubist Pharmaceuticals (CBST) 61.05 $CBST
Financial Results, Clinical Trial Initiations, Drug Designations, Appointments, and Study Results - Research Reports on Cubist, Jazz, InterMune, NPS Pharmaceuticals and ACADIA
PR Newswire - Wed Jul 30, 8:00AM CDT
Today, Analysts Review released its research reports regarding Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), InterMune, Inc. (NASDAQ: ITMN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5256-100free.
Cubist to Present at August Investor Conference
Business Wire - Mon Jul 28, 8:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss Cubist's business activities and financial outlook at investor conferences during August 2013.
SmarTrend Watching for Potential Rebound in Shares of Cubist Pharmaceuticals After 4.75% Loss
Comtex SmarTrend(R) - Wed Jul 23, 4:09PM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $58.50 to a high of $63.56. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $63.14 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:10PM CDT
Cubist's (CBST) second quarter earnings were short of the Zacks Consensus Estimate.
Downgrade Alert for Cubist Pharmaceuticals (CBST)
Comtex SmarTrend(R) - Wed Jul 23, 7:08AM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $65.70 on volume of 705,000 shares, above average daily volume of 612,000. There is potential upside of 24.5% for shares of Cubist Pharmaceuticals based on a current price of $65.70 and an average consensus analyst price target of $81.79. The stock should find initial resistance at its 50-day moving average (MA) of $68.03 and further resistance at its 200-day MA of $68.96.
Cubist Reports Second Quarter 2014 Financial Results
Business Wire - Tue Jul 22, 3:00PM CDT
--Non-GAAP Adjusted Operating Income of $41.4 Million; GAAP Operating Income of $42.2 Million
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Roundtable: 3 Stocks Preparing to Shock the Market
Motley Fool Staff - Motley Fool - Sat Jul 19, 4:16PM CDT
Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out. George Budwell : Next week, I expect Cubist...
Investing to Fight Toilet and Elevator Superbugs
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Jul 19, 2:00PM CDT
A big thank-you to our friends at FierceHealthcare for an incredible story about how a recent study indicated that hospital elevator buttons might have a higher prevalence of bacteria colonization than toilets. Yes, you read that correctly....
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
Cubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014
Business Wire - Tue Jul 15, 8:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its second quarter 2014 financial results at 4:00 p.m. ET on Tuesday, July 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its second quarter financial results, business activities, and financial outlook.
Cidara Therapeutics - "Back to the Rodeo"
ACCESSWIRE - Tue Jul 01, 10:09AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / Cidara Therapeutics today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Dr. Jeff Stein. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
3 Biotech Stocks with Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
One key reason the biotech industry has soared over the past two years is that a number of companies gained regulatory approvals for drugs with stunning commercial potentials. This industry-wide rise, however, has been pockmarked by companies whose...
Clinical Trial Data, NDA Submissions, and Board Changes - Analyst Notes on Alkermes, Cubist, Repligen, Flamel Technologies and Chimerix
PR Newswire - Wed Jun 25, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alkermes plc (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Repligen Corporation (NASDAQ: RGEN), Flamel Technologies SA (NASDAQ: FLML) and Chimerix, Inc. (NASDAQ: CMRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4090-100free.
Cepheid Forms Pharma Alliance to Fight Antibiotic Resistance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 4:45PM CDT
Following the news, Cepheid's (CPHD) share price rose 1.4% to eventually close at $47.78 on Friday
Cubist and Durata Heat Up Antibiotic Market
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Antibiotics are on a comeback. And Cubist Pharmaceuticals is in the middle of it. Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every antibiotic drugmaker. On Friday, the agency approved its second...
Cubist Pharmaceuticals (CBST) Is Water-Logged And Getting Wetter Today
at The Street - Mon Jun 23, 11:24AM CDT
Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication.
Will This Price Target Increase Help Cubist Pharmaceuticals (CBST) Stock Today?
at The Street - Mon Jun 23, 8:23AM CDT
Jefferies increased its price target on Cubist Pharmaceuticals (CBST) to $88 and set a "buy" rating. New antibiotic launches that will expand profit margin drove the firm's decision.
FDA approves Cubist antibiotic for skin infections
By MATTHEW PERRONE - AP - Fri Jun 20, 5:32PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.
Financial Results, Clinical Trial Initiations, Drug Designations, Appointments, and Study Results - Research Reports on Cubist, Jazz, InterMune, NPS Pharmaceuticals and ACADIA
PR Newswire - Wed Jul 30, 8:00AM CDT
Today, Analysts Review released its research reports regarding Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), InterMune, Inc. (NASDAQ: ITMN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5256-100free.
Cubist to Present at August Investor Conference
Business Wire - Mon Jul 28, 8:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss Cubist's business activities and financial outlook at investor conferences during August 2013.
SmarTrend Watching for Potential Rebound in Shares of Cubist Pharmaceuticals After 4.75% Loss
Comtex SmarTrend(R) - Wed Jul 23, 4:09PM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $58.50 to a high of $63.56. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $63.14 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:10PM CDT
Cubist's (CBST) second quarter earnings were short of the Zacks Consensus Estimate.
Downgrade Alert for Cubist Pharmaceuticals (CBST)
Comtex SmarTrend(R) - Wed Jul 23, 7:08AM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded from Outperform to Market Perform at JMP Securities today. The stock closed yesterday at $65.70 on volume of 705,000 shares, above average daily volume of 612,000. There is potential upside of 24.5% for shares of Cubist Pharmaceuticals based on a current price of $65.70 and an average consensus analyst price target of $81.79. The stock should find initial resistance at its 50-day moving average (MA) of $68.03 and further resistance at its 200-day MA of $68.96.
Cubist Reports Second Quarter 2014 Financial Results
Business Wire - Tue Jul 22, 3:00PM CDT
--Non-GAAP Adjusted Operating Income of $41.4 Million; GAAP Operating Income of $42.2 Million
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Roundtable: 3 Stocks Preparing to Shock the Market
Motley Fool Staff - Motley Fool - Sat Jul 19, 4:16PM CDT
Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out. George Budwell : Next week, I expect Cubist...
Investing to Fight Toilet and Elevator Superbugs
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Jul 19, 2:00PM CDT
A big thank-you to our friends at FierceHealthcare for an incredible story about how a recent study indicated that hospital elevator buttons might have a higher prevalence of bacteria colonization than toilets. Yes, you read that correctly....
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
Cubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014
Business Wire - Tue Jul 15, 8:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its second quarter 2014 financial results at 4:00 p.m. ET on Tuesday, July 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its second quarter financial results, business activities, and financial outlook.
Cidara Therapeutics - "Back to the Rodeo"
ACCESSWIRE - Tue Jul 01, 10:09AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / Cidara Therapeutics today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Dr. Jeff Stein. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
3 Biotech Stocks with Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Fri Jun 27, 4:00PM CDT
One key reason the biotech industry has soared over the past two years is that a number of companies gained regulatory approvals for drugs with stunning commercial potentials. This industry-wide rise, however, has been pockmarked by companies whose...
Clinical Trial Data, NDA Submissions, and Board Changes - Analyst Notes on Alkermes, Cubist, Repligen, Flamel Technologies and Chimerix
PR Newswire - Wed Jun 25, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alkermes plc (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Repligen Corporation (NASDAQ: RGEN), Flamel Technologies SA (NASDAQ: FLML) and Chimerix, Inc. (NASDAQ: CMRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4090-100free.
Cepheid Forms Pharma Alliance to Fight Antibiotic Resistance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 4:45PM CDT
Following the news, Cepheid's (CPHD) share price rose 1.4% to eventually close at $47.78 on Friday
Cubist and Durata Heat Up Antibiotic Market
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Antibiotics are on a comeback. And Cubist Pharmaceuticals is in the middle of it. Gone are the days when it seemed the Food and Drug Administration had a bone to pick with every antibiotic drugmaker. On Friday, the agency approved its second...
Cubist Pharmaceuticals (CBST) Is Water-Logged And Getting Wetter Today
at The Street - Mon Jun 23, 11:24AM CDT
Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Cubist Gains FDA Approval for Sivextro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 10:50AM CDT
Cubist's (CBST) Sivextro gained FDA approval for the ABSSSI indication.
Will This Price Target Increase Help Cubist Pharmaceuticals (CBST) Stock Today?
at The Street - Mon Jun 23, 8:23AM CDT
Jefferies increased its price target on Cubist Pharmaceuticals (CBST) to $88 and set a "buy" rating. New antibiotic launches that will expand profit margin drove the firm's decision.
FDA approves Cubist antibiotic for skin infections
By MATTHEW PERRONE - AP - Fri Jun 20, 5:32PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.
